HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sunitinib Malate

HCID 6456015
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
341031-54-7
Standard SMILES
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
InChIKey
LBWFXVZLPYTWQI-IPOVEDGCSA-N
Molecular formula
C26H33FN4O7
Average molar mass
532.6 g/mol
Monoisotopic mass
532.23332757

Overview

Sunitinib malate is an organic molecular entity. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It contains a sunitinib.

Names & identifiers

Preferred name
Sunitinib Malate
IUPAC
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
English name
Sunitinib Malate
Molecular formula
C26H33FN4O7
Molecular weight
532.56

Names & synonyms

Sunitinib malate341031-54-7SU011248 L-malate saltsunitinib L-malatePHA-290940ADSU010398SU-011248 L-malate saltDTXSID4046492LVX8N1UT73SU-010398DTXCID801476195NSC736511
Show more names
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate(Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrCS-308NSC2677SU112248NSC 2677NSC-2677SU 011248Sunitinib MaL
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)RefChem:56081Sunitinib malate [USAN]MFCD08282795Sunitinib (Malate)PDGF TK antagonistSutent (TN)

Properties

Computed structural properties

Topological polar surface area
172 Ų
Hydrogen bond donors
6
Hydrogen bond acceptors
9
Rotatable bonds
10
Heavy atoms
38
Formal charge
0
Complexity
765

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
189 · 189-191°C
storage temp.
room temp
solubility
10 mg/mL · DMSO: >10mg/mL
form
powder
pka
8.95 · 8.95
color
Orange
Stability
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey
XGQXULJHBWKUJY-LYIKAWCPSA-N
SMILES
[C@@H](O)(C(=O)O)CC(=O)O.C(/C1NC(C)=C(C(=O)NCCN(CC)CC)C=1C)=C1/C(NC2=CC=C(F)C=C/12)=O |&1:0,r|
CAS DataBase Reference
341031 · 341031-54-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
11248 · SU011248; sunitinib malate

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H360 (93.8%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P264, P270, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 48 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesRepr. 1B (93.8%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sunitinib malate

vMost-DILI-concern

8

Box warning

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
2
ridadr
UN3077
hs_code
2933990099
risk_code
61-2-48/25-36/37-22-53
Signal word
Danger
Symbol(GHS)
GHS08
hazard_code
T
safety_code
53-22-36/37-24/25
hazard_class
9
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 2 items

SUNITINIB MALATE

Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]

MeSH Pharmacological Classification · 3 items

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Agents that inhibit PROTEIN KINASES.

Applications · 6 items

UsesAnti-cancer drugs

DescriptionSunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3. It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src. Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively). It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day. Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.

UsesSunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

UsesSunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit

UsesA multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.

General DescriptionSunitinib is available in 12.5-, 25-, and 50-mg capsules fororal administration for the treatment of advanced RCC andGIST upon the failure of imatinib. The agent is a multikinaseinhibitor and has been shown to inhibit PDGF-R,VEGF-R, Kit, RET, and the colony-stimulating factor receptor(CSR-1R). The result of this spectrum of activity isa slowing of tumor progression and inhibition of angiogenesisboth of which are useful in the highly vascularizedcancers, RCC and GIST. The median TTP (time to tumorprogression) was 27.3 weeks for sunitinib and 6.4 weeks with a median time of 24.1 weeks for sunitinib and 6 weeksfor placebo. The agent is well absorbed upon oral administration,and both the parent and major metabolite are highly(90%–95%) protein bound. Metabolism is mediated primarilyby CYP3A4 to give the N-desethyl derivative, which isthe major metabolite (23%–37%), equally active with theparent and undergoes further metabolism by CYP3A4. Theterminal elimination half-life for the parent and N-desethylderivative are 40 to 60 hours and 80 to 110 hours, respectively.Elimination occurs primarily via the feces. Commonadverse effects of sunitinib include fatigue, diarrhea, yellowskin discoloration, anorexia, nausea, and mucositis.Mild myelosuppression has been reported in patients withGIST including neutropenia, lymphopenia, thrombocytopenia,and anemia. There have been reports of cardiotoxicityincluding decreases in left ventricular ejectionfraction, which occurred in 11% of patients during a GISTstudy.

Related reactions

39 records
New reaction record
HRID 84784 reaction equation
HRID 84784As product
HRID 84790 reaction equation
HRID 84790As reactant
HRID 1500395 reaction equation
HRID 1500395As product
HRID 1918241 reaction equation
HRID 1918241As product
HRID 1918242 reaction equation
HRID 1918242As product
HRID 1918243 reaction equation
HRID 1918243As product
HRID 1918244 reaction equation
HRID 1918244As product
HRID 1918245 reaction equation
HRID 1918245As product
PreviousPage 1 of 5

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
341031-54-7
PubChem CID
6456015
DTXSID
DTXSID4046492
ChEMBL
CHEMBL1567
ChEBI
CHEBI:232546
UNII
LVX8N1UT73
EC Number
638-825-9
FDA UNII
8 N1UT73 · LVX8N1UT73
NCI Drug Dictionary
sunitinib malate
Comptox DTXSID
4046492 · DTXSID4046492
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
360 · H360-H372
Precautionary statements
201 · P201-P308+P313
Hazard Codes
T
Risk Statements
61 · 61-2-48/25-36/37-22-53
Safety Statements
53 · 53-22-36/37-24/25
RIDADR
3077 · UN3077
WGK Germany
2 · 2
HazardClass
9 · 9
HS Code
2933990099 · 2933990099
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
1 BSTOT · Repr. 1BSTOT RE 1 Oral
Limited Quantities
5 kg · 5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
Hazard statements
H360-H372
Limited Quantities
5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
Hazard Classifications
Repr. 1BSTOT RE 1 Oral
Precautionary statements
P201-P308+P313